Engineers Gate Manager LP Arcturus Therapeutics Holdings Inc. Transaction History

Engineers Gate Manager LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$23.94 - $32.36 $172,894 - $233,703	7,222 Added 69.51%	17,612 $505,000
Q1 2023 May 15, 2023	BUY	$14.72 - $23.97 $152,940 - $249,048	10,390 New	10,390 $249,000
Q3 2021 Nov 15, 2021	SELL	$27.88 - $58.25 $829,402 - $1.73 Million	-29,749 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$25.79 - $42.11 $335,888 - $548,440	13,024 Added 77.87%	29,749 $1.01 Million
Q1 2021 May 17, 2021	BUY	$38.75 - $86.92 $240,560 - $539,599	6,208 Added 59.03%	16,725 $691,000
Q4 2020 Feb 16, 2021	BUY	$34.61 - $123.66 $363,993 - $1.3 Million	10,517 New	10,517 $456,000
Q3 2020 Nov 16, 2020	SELL	$37.49 - $63.19 $605,988 - $1.02 Million	-16,164 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$12.66 - $58.27 $79,150 - $364,304	-6,252 Reduced 27.89%	16,164 $756,000
Q1 2020 May 15, 2020	BUY	$9.31 - $18.26 $208,692 - $409,316	22,416 New	22,416 $305,000
Q4 2019 Feb 14, 2020	SELL	$8.93 - $12.41 $116,473 - $161,863	-13,043 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.8 - $14.5 $114,778 - $189,123	13,043 New	13,043 $134,000

179

25.6M

195K

133K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $411M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.